AngioLab, Inc. Logo

AngioLab, Inc.

Develops anti-angiogenic therapeutics and foods for angiogenesis-related diseases.

251280 | KO

Overview

Corporate Details

ISIN(s):
KR7251280004
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노3로 65, 대전광역시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

AngioLab, Inc. is a biotechnology company established in 1999 that specializes in the research and development of therapeutics based on angiogenesis inhibition. The company develops pharmaceuticals and health functional foods designed to treat a variety of angiogenesis-related diseases. Its core technology focuses on the discovery and application of anti-angiogenic and matrix metalloproteinase (MMP) inhibitors. AngioLab manages a pipeline of drug candidates, advancing them through clinical trials to create novel treatments for conditions driven by abnormal blood vessel formation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-10 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 63.7 KB
2025-09-10 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.7 KB
2025-07-17 00:00
Share Issue/Capital Change
기타주요경영사항(자율공시) (전환우선주의 보통주 전환)
Korean 7.8 KB
2025-04-23 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.7 KB
2025-04-08 00:00
Share Issue/Capital Change
기타주요경영사항(자율공시) (전환우선주의 보통주 전환)
Korean 7.8 KB
2025-03-27 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 20.8 KB
2025-03-20 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.9 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 9.6 KB
2025-03-18 00:00
Annual / Quarterly Financial Statement
사업보고서 (2024.12)
Korean 342.5 KB
2025-03-12 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 261.5 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 12.8 KB
2025-03-07 00:00
Remuneration Information
[기재정정]주식매수선택권부여에관한신고
Korean 19.9 KB
2025-03-07 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 18.7 KB
2025-03-04 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 42.6 KB
2025-02-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.1 KB

Automate Your Workflow. Get a real-time feed of all AngioLab, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AngioLab, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AngioLab, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

VALIRX PLC Logo
Advancing oncology & women's health therapeutics and offering preclinical research services.
United Kingdom
VAL
VALUE GOLF Inc. Logo
A golf services hub offering reservations, solo player bookings, e-commerce, lessons, and tours.
Japan
3931
Value HR Co., Ltd. Logo
Offers a health management platform and consulting for corporate health insurance societies in Japan.
Japan
6078
Global OTA for curated tours & experiences, focusing on travel to and from Japan.
Japan
7048
A South Korean travel company offering global tour packages, flights, hotels, and corporate travel.
South Korea
094850
Virax Biolabs Group Ltd Logo
Specializes in T-cell immunity tests and diagnostics for profiling viral disease responses.
United States of America
VRAX
VisionSys AI Inc Logo
Develops AI-powered brain-computer interfaces for the healthcare and biotech sectors.
United States of America
VSA
Vivesto Logo
Develops and licenses novel cancer therapies for humans and animals using proprietary drug delivery.
Sweden
VIVE
Vor Biopharma Inc. Logo
Clinical-stage biotech developing next-gen medicines that target the root cause of autoimmune disease.
United States of America
VOR
Voronoi, Inc. Logo
Develops selective kinase inhibitors and targeted protein degraders for precision oncology.
South Korea
310210

Talk to a Data Expert

Have a question? We'll get back to you promptly.